US5907174016 - MESO - A4004R (XNAS)
MESOBLAST SP.ADRS 144A/10 Hinterlegungsschein
5,77 EUR
Aktuelle Kurse von MESOBLAST SP.ADRS 144A/10
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
MESO
|
USD
|
19.09.2024 21:59
|
6,44 USD
| 6,17 USD | 4,38 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -1,91 % | -1,61 % | -16,80 % | 175,79 % | 128,39 % | -53,53 % |
Firmenprofil zu MESOBLAST SP.ADRS 144A/10 Hinterlegungsschein
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Unternehmensdaten MESOBLAST SP.ADRS 144A/10 Hinterlegungsschein
Name MESOBLAST SP.ADRS 144A/10
Firma Mesoblast Limited
Symbol MESO
Website https://www.mesoblast.com
Heimatbörse
Frankfurt
WKN A4004R
ISIN US5907174016
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Marktkapitalisierung 696 Mio
Land Australien
Währung EUR
Mitarbeiter 0,1 T
Adresse 55 Collins Street, 3000 Melbourne
IPO Datum 2010-01-20
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
28.10.2015 | MBLTY | MESO |
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | MESO |
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024